SI2044025T1 - Kinolinonski derivati in njihovi farmacevtski sestavki - Google Patents

Kinolinonski derivati in njihovi farmacevtski sestavki

Info

Publication number
SI2044025T1
SI2044025T1 SI200731103T SI200731103T SI2044025T1 SI 2044025 T1 SI2044025 T1 SI 2044025T1 SI 200731103 T SI200731103 T SI 200731103T SI 200731103 T SI200731103 T SI 200731103T SI 2044025 T1 SI2044025 T1 SI 2044025T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical compositions
quinolinone derivatives
quinolinone
derivatives
pharmaceutical
Prior art date
Application number
SI200731103T
Other languages
English (en)
Inventor
Olivier Lohse
Stephanie Monnier
Jean-Louis Reber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2044025T1 publication Critical patent/SI2044025T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200731103T 2006-06-30 2007-07-02 Kinolinonski derivati in njihovi farmacevtski sestavki SI2044025T1 (sl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
EP07819899A EP2044025B1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions
PCT/EP2007/056632 WO2008000839A1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SI2044025T1 true SI2044025T1 (sl) 2013-01-31

Family

ID=38610531

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731103T SI2044025T1 (sl) 2006-06-30 2007-07-02 Kinolinonski derivati in njihovi farmacevtski sestavki

Country Status (28)

Country Link
US (2) US8198450B2 (sl)
EP (1) EP2044025B1 (sl)
JP (1) JP5253392B2 (sl)
KR (1) KR101402398B1 (sl)
CN (1) CN101479245B (sl)
AU (1) AU2007264946B2 (sl)
BR (1) BRPI0713951B8 (sl)
CA (1) CA2654801C (sl)
CY (3) CY1113733T1 (sl)
DK (1) DK2044025T3 (sl)
ES (1) ES2396987T3 (sl)
FR (2) FR20C1054I1 (sl)
HK (1) HK1127597A1 (sl)
HR (1) HRP20121074T1 (sl)
HU (2) HUS2000043I1 (sl)
IL (1) IL195796A (sl)
LT (2) LTC2044025I2 (sl)
LU (2) LUC00185I2 (sl)
MA (1) MA30540B1 (sl)
MX (1) MX2008016542A (sl)
MY (1) MY150468A (sl)
NO (3) NO341709B1 (sl)
NZ (1) NZ573292A (sl)
PL (1) PL2044025T3 (sl)
PT (1) PT2044025E (sl)
SI (1) SI2044025T1 (sl)
WO (1) WO2008000839A1 (sl)
ZA (1) ZA200809948B (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
AU2008294473B2 (en) 2007-09-05 2013-12-05 Rigel Pharmaceuticals, Inc. Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one) -6-yl]-5-fluoro-N2-[3-methylaminocar-bonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
AU2014229361B2 (en) 2013-03-14 2016-08-04 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
WO2017055506A1 (en) 2015-09-29 2017-04-06 Laboratorios Lesvi, S.L. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20100399A1 (es) 2003-04-02 2010-06-01 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
JP4516064B2 (ja) * 2003-04-04 2010-08-04 ノバルティス アーゲー 気道疾患の処置のためのキノリン−２−オン誘導体
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
CN101142217B (zh) 2005-03-21 2010-12-08 伊莱利利公司 咪唑并哒嗪化合物
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
LUC00188I2 (sl) 2024-07-01
BRPI0713951B1 (pt) 2019-08-13
IL195796A0 (en) 2009-09-01
HUS2000053I1 (hu) 2020-12-28
NO20090312L (no) 2009-01-28
AU2007264946A1 (en) 2008-01-03
BRPI0713951B8 (pt) 2021-05-25
CY1113733T1 (el) 2016-06-22
PL2044025T3 (pl) 2013-02-28
CY2020038I2 (el) 2021-03-12
US20120316142A1 (en) 2012-12-13
DK2044025T3 (da) 2013-01-14
CA2654801C (en) 2014-08-19
US8198450B2 (en) 2012-06-12
KR20090023651A (ko) 2009-03-05
CY2020041I2 (el) 2021-03-12
HUS2000043I1 (hu) 2020-12-28
NO2020041I1 (no) 2020-11-23
EP2044025B1 (en) 2012-10-03
KR101402398B1 (ko) 2014-06-03
CY2020038I1 (el) 2021-03-12
NO2020044I1 (no) 2020-12-07
MX2008016542A (es) 2009-01-19
JP2009541455A (ja) 2009-11-26
IL195796A (en) 2016-03-31
US20090325912A1 (en) 2009-12-31
LTPA2020535I1 (lt) 2020-12-28
ES2396987T3 (es) 2013-03-01
PT2044025E (pt) 2012-12-17
AU2007264946B2 (en) 2011-01-20
ZA200809948B (en) 2009-05-25
MY150468A (en) 2014-01-30
FR20C1063I1 (fr) 2021-01-22
EP2044025A1 (en) 2009-04-08
JP5253392B2 (ja) 2013-07-31
CN101479245A (zh) 2009-07-08
FR20C1054I1 (fr) 2020-12-25
LTC2044025I2 (lt) 2022-10-10
CA2654801A1 (en) 2008-01-03
NZ573292A (en) 2011-03-31
NO341709B1 (no) 2018-01-02
MA30540B1 (fr) 2009-06-01
BRPI0713951A2 (pt) 2012-12-04
LTPA2020538I1 (lt) 2021-01-11
CY2020041I1 (el) 2021-03-12
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31
LUC00185I2 (sl) 2024-07-01
WO2008000839A1 (en) 2008-01-03
CN101479245B (zh) 2013-05-22

Similar Documents

Publication Publication Date Title
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
HUS2000053I1 (hu) Kinolinszármazékok és gyógyászati készítményeik
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
PL1861387T3 (pl) Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
IL190292A (en) History of pyridopyrimidinone and their pharmaceutical preparations
IL192613A (en) Cycloalkylamines and their pharmaceutical compositions
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
SI2154966T1 (sl) Benzimidazoli in njihovi farmacevtski sestavki
PT1861387E (pt) Derivados de benzimidazol e composições farmacêuticas dos mesmos
HK1139153A1 (en) Quinolone compound and pharmaceutical composition
IL232457A0 (en) Quinolone compound and pharmaceutical preparation
GB0610090D0 (en) Particulate drug compositions and their uses
IL197273A0 (en) Pharmaceutical and sunscreen compositions comprising caspase-14
EP2070919A4 (en) SPIROCHINONE COMPOUND AND PHARMACEUTICAL COMPOSITION
GB0614365D0 (en) Pharmaceutical compositions and their use
PT2220047E (pt) Derivados de quinolina, composições farmacêuticas que os contêm e sua utilização
IL196318A0 (en) (s)-(-)-amlodipine camsylate derivatives and pharmaceutical compositions containing
EP2114404A4 (en) COMPOUND AND PHARMACEUTICAL COMPOSITION
GB0701295D0 (en) Z-stilbenes derivatives and the pharmaceutical composition thereof
HK1145492A1 (en) Quinoline derivatives, pharmaceutical compositions comprising them, and use thereof
GB0617340D0 (en) Anti-malarial pharmaceutical composition